8-K: Titan Pharmaceuticals Converts Preferred Stock to Common, Increasing Share Count

Titan Pharmaceuticals, Inc. has completed the conversion of Series AA and Series B Convertible Preferred Stock held by The Sire Group Ltd. and Blue Harbour Asset Management L.L.C-FZ into common stock, resulting in the issuance of 415,000 new common shares.

Summary

• Titan Pharmaceuticals, Inc. (TTNP) reported the conversion of preferred stock into common stock.
• The Sire Group Ltd. converted 139,882 shares of Series AA Convertible Preferred Stock into 150,087 shares of common stock on May 30, 2025.
• The Series AA Preferred Stock was originally issued on September 13, 2023, with 950,000 shares sold at $10.00 per share, totaling $9,500,000.
• Blue Harbour Asset Management L.L.C-FZ converted 79,773 shares of Series B Convertible Preferred Stock into 265,913 shares of common stock on May 30, 2025.
• The Series B Preferred Stock was originally issued on March 29, 2025, with 100,000 shares sold at $10.00 per share, totaling $1,000,000.
• Both conversions were exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and the newly issued common shares carry a Rule 144 restrictive legend.
• Conversion terms for Series AA Preferred Stock were based on a $0.466 initial conversion price, while Series B Preferred Stock used a $3.00 initial conversion price, both subject to adjustments.
• Both preferred stock series contain limitations preventing holders from acquiring more than 19.99% of outstanding common stock or the maximum percentage permissible under Nasdaq rules without shareholder approval.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of capital structure changes (preferred stock conversions) and does not contain information that inherently indicates a positive or negative operational or financial performance outcome. The dilution from conversion is a known consequence of such instruments.

Positives

• The original issuance of Series AA and Series B Preferred Stock provided Titan Pharmaceuticals with $10,500,000 in aggregate capital.
• The conversion of preferred stock into common stock simplifies the company's capital structure by reducing the number of outstanding preferred shares.

Negatives

• The conversion resulted in the issuance of 415,000 new common shares, leading to dilution for existing common shareholders.

Risks

• Potential future dilution of common stock if remaining convertible preferred shares are converted.
• Increased common share float could put downward pressure on the stock price.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future operations, financial performance, or strategic direction beyond the mechanics of the stock conversions.

Management Comments

• The report was signed by Chay Weei Jye, Chief Executive Officer of Titan Pharmaceuticals, Inc.

Industry Context

This filing primarily details a company-specific capital structure event, specifically the conversion of preferred stock into common stock. It does not provide information that directly relates to broader industry trends or competitive landscape within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The issuance of additional common shares will dilute the ownership percentage of existing common shareholders.

Key Dates

Keywords

Titan Pharmaceuticals, TTNP, Preferred Stock Conversion, Common Stock Issuance, SEC Filing, 8-K, Capital Structure, Dilution, The Sire Group, Blue Harbour Asset Management